Sunovion Pharmaceuticals Europe has revealed that Latuda (lurasidone), a new once-daily oral treatment, is available in the UK to treat schizophrenia in adults.

Latude is an atypical antipsychotic, which was originally developed by Sumitomo Dainippon Pharma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug, which has no appreciable affinity for histamine (H1) and muscarinic (M1) receptors, is characterised by high-affinity binding for dopamine (D2) and serotonin (5HT2A and 5HT7) receptors.

"We believe there is an unmet need in the UK for treatments that provide both efficacy and tolerability."

Sunovion Pharmaceuticals executive vice-president and chief commercial officer Richard Russell said: "We believe there is an unmet need in the UK for treatments that provide both efficacy and tolerability, so [we] are pleased to offer Latuda as a new treatment option for people living with schizophrenia and the healthcare professionals who treat them."

The licensing for the oral treatment was based on short and long-term clinical studies, which found it to be effective in treating both positive and negative symptoms in psychotic patients with schizophrenia.

Significant reductions in symptoms against a placebo were witnessed as early as day four in both studies, according to the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In short-term and long-term studies, the common side effects seen with the use of Latuda include insomnia, somnolence, restlessness or akathisia, difficulty moving, slow movements, muscle stiffness or tremor, weight gain and nausea.

Schizophrenia is a severe and chronic mental illness. Approximately 630,000 people could suffer from it during their lifetime in the UK.